Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03PDY
|
|||
Former ID |
DNC001298
|
|||
Drug Name |
SB-332235
|
|||
Synonyms |
1-(4-Chloro-2-hydroxy-3-sulfamoyl-phenyl)-3-(2,3-dichlorophenyl)urea; 276702-15-9; SB 332235; UNII-5HLP8UVL8M; 5HLP8UVL8M; CHEMBL3819292; WTLRWOHEKQGKDS-UHFFFAOYSA-N; SCHEMBL1535901; sb332235; MolPort-042-624-550; ZINC3990011; BDBM50182254; 1-(4-chloro-2-hydroxy-3-sulfamoyl-phenyl)-3-(2,3-dichlorophenyl)urea; AKOS027470251; N-(4-Chloro-2hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) urea; n-(4-chloro-2-hydroxy-3-aminosulfonylphenyl)-n'-(2,3-dichlorophenyl)urea; N-(4-Chloro-2-hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) Urea; N-(3-(aminosulfonyl)-4-chloro-2-hydroxyphenyl)-N'-(2,3-dichlorophenyl) urea
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Discontinued in Phase 1 | [1] | |
Company |
GlaxoSmithKline
|
|||
Structure |
Download2D MOL |
|||
Formula |
C13H10Cl3N3O4S
|
|||
Canonical SMILES |
C1=CC(=C(C(=C1)Cl)Cl)NC(=O)NC2=C(C(=C(C=C2)Cl)S(=O)(=O)N)O
|
|||
InChI |
1S/C13H10Cl3N3O4S/c14-6-2-1-3-8(10(6)16)18-13(21)19-9-5-4-7(15)12(11(9)20)24(17,22)23/h1-5,20H,(H2,17,22,23)(H2,18,19,21)
|
|||
InChIKey |
WTLRWOHEKQGKDS-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 276702-15-9
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | C-X-C chemokine receptor type 2 (CXCR2) | Target Info | Antagonist | [2], [3] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
Chemokine signaling pathway | ||||
Endocytosis | ||||
Epithelial cell signaling in Helicobacter pylori infection | ||||
NetPath Pathway | TNFalpha Signaling Pathway | |||
Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
Interleukin signaling pathway | ||||
Pathway Interaction Database | IL8- and CXCR2-mediated signaling events | |||
Reactome | Chemokine receptors bind chemokines | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014165) | |||
REF 2 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | |||
REF 3 | A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol. 2002 Dec 1;169(11):6435-44. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.